SALMONELLA

Volver

Resultados 48 resultados LastUpdate Última actualización: 30/06/2016 [05:39:00] pdf PDF




Solicitudes de Patente publicadas en los últimos 90 días / Patent Applications published in the last 90 days



Página 1 de 2 nextPage   Mostrar por página


NUCLEOTIDE SEQUENCE CODING FOR A TOLC AND A DEFINED AMINO ACID SEQUENCE

Nº publicación: BRPI0307873A2 21/06/2016

Solicitante:
R ULF RAPP [DE]

Resumen de: CA2513192A1

The invention relates to a nucleotide sequence coding for a TolC and a defin ed amino acid sequence, said defined amino acid sequence being inserted in the permissive, membrane-external area of the TolC, and several uses thereof, particularly bacteria containing such a nucleotide sequence.



traducir


 

NUCLEOTIDE SEQUENCE CODING FOR A TOLC AND A DEFINED AMINO ACID SEQUENCE

Nº publicación: BRPI0307873A2 21/06/2016

Solicitante:
R ULF RAPP [DE]

Resumen de: CA2513192A1

The invention relates to a nucleotide sequence coding for a TolC and a defin ed amino acid sequence, said defined amino acid sequence being inserted in the permissive, membrane-external area of the TolC, and several uses thereof, particularly bacteria containing such a nucleotide sequence.



traducir


 

VACCINE VECTOR COMPRISING ATTENUATED SALMONELLA ENTERICA TYPHIMURIUM WHICH ARE MUTANTS FOR THE GENE FIS, VACCINE COMPRISING SAID VECTOR AND USE OF SAID VECTOR

Nº publicación: WO2016090440A1 16/06/2016

Solicitante:
UNICAMP [BR]

Resumen de: WO2016090440A1

The development of attenuated live vaccines against salmonellosis has increased over the past years due to the nonexistence of completely effective vaccine formulations which enable different S. enterica serovars to be more effectively controlled. The development of a safe strain that is capable of inducing an efficient immune response involves the production of various attenuated mutants that can be clinically tested or which have unique features that can be combined with other specific mutations, generating increasingly safe and efficient strains. The present invention relates to a vaccine vector comprising mutants for thegene fis, wherein the protein that results from expression thereof, Fis, associates with the bacterial nucleoid regulating the expression of various genes, many of which are related to bacterial pathogenicity. The present invention also relates to a vaccine comprising said mutant strains which generate a response capable of inducing efficient protection against salmonellosis.



traducir


 

HYPERBLEBBING SHIGELLA STRAINS

Nº publicación: JP2016105736A 16/06/2016

Resumen de: WO2011036564A2

Hyperblebbing Shigella strains are generated by disrupting one or more components of the Tol-Pal system. The blebs from these strains are useful immunogens for vaccination. The individual proteins found in these blebs can also be used as immunogens.



traducir


 

ESCHERICHIA COLI AS A MARKER FOR HYPERTRIGLYCERIDEMIA

Nº publicación: US2016168627A1 16/06/2016

Solicitante:
NESTEC SA [CH]

Resumen de: WO2015007464A1

The present invention relates to predicting the risk of developing hypertriglyceridemia in a subject by quantitating the amount of enterobacteria, e.g., E. coli, in the subject's gastrointestinal system. The invention also relates to treating a subject with hypertriglyceridemia or at risk of having the condition.



traducir


 

O-ANTIGEN CARBOHYDRATE CHAIN EXTENDED S ALMONELLA PARATYPHI A AND USE THEREOF

Nº publicación: WO2016090980A1 16/06/2016

Solicitante:
INST OF BIOTECHNOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES CHINA [CN]

Resumen de: WO2016090980A1

Provided are an O-antigen carbohydrate chain extended Salmonella paratyphi A and a use thereof. The method comprises the following steps: inactivating a cld geneof the enzyme for controlling the O-antigen chain length of Salmonella paratyphi A, and obtaining Salmonella paratyphi A defects in a cld gene of the enzyme for controlling the O-antigen chain length; overexpressing a cld LT2 gene of the enzyme for controlling the O-antigen chain length of Salmonella typhimurium in the Salmonella paratyphi A defects in the cld gene of the enzyme for controlling the O-antigen chain length, and then extending the O-antigen carbohydrate chain length of Salmonella paratyphi A.



traducir


 

HYPERBLEBBING SHIGELLA STRAINS

Nº publicación: JP2016105736A 16/06/2016

Resumen de: WO2011036564A2

Hyperblebbing Shigella strains are generated by disrupting one or more components of the Tol-Pal system. The blebs from these strains are useful immunogens for vaccination. The individual proteins found in these blebs can also be used as immunogens.



traducir


 

VACCINE VECTOR COMPRISING ATTENUATED SALMONELLA ENTERICA TYPHIMURIUM WHICH ARE MUTANTS FOR THE GENE FIS, VACCINE COMPRISING SAID VECTOR AND USE OF SAID VECTOR

Nº publicación: WO2016090440A1 16/06/2016

Solicitante:
UNICAMP [BR]

Resumen de: WO2016090440A1

The development of attenuated live vaccines against salmonellosis has increased over the past years due to the nonexistence of completely effective vaccine formulations which enable different S. enterica serovars to be more effectively controlled. The development of a safe strain that is capable of inducing an efficient immune response involves the production of various attenuated mutants that can be clinically tested or which have unique features that can be combined with other specific mutations, generating increasingly safe and efficient strains. The present invention relates to a vaccine vector comprising mutants for thegene fis, wherein the protein that results from expression thereof, Fis, associates with the bacterial nucleoid regulating the expression of various genes, many of which are related to bacterial pathogenicity. The present invention also relates to a vaccine comprising said mutant strains which generate a response capable of inducing efficient protection against salmonellosis.



traducir


 

O-ANTIGEN CARBOHYDRATE CHAIN EXTENDED S ALMONELLA PARATYPHI A AND USE THEREOF

Nº publicación: WO2016090980A1 16/06/2016

Solicitante:
INST OF BIOTECHNOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES CHINA [CN]

Resumen de: WO2016090980A1

Provided are an O-antigen carbohydrate chain extended Salmonella paratyphi A and a use thereof. The method comprises the following steps: inactivating a cld geneof the enzyme for controlling the O-antigen chain length of Salmonella paratyphi A, and obtaining Salmonella paratyphi A defects in a cld gene of the enzyme for controlling the O-antigen chain length; overexpressing a cld LT2 gene of the enzyme for controlling the O-antigen chain length of Salmonella typhimurium in the Salmonella paratyphi A defects in the cld gene of the enzyme for controlling the O-antigen chain length, and then extending the O-antigen carbohydrate chain length of Salmonella paratyphi A.



traducir


 

ESCHERICHIA COLI AS A MARKER FOR HYPERTRIGLYCERIDEMIA

Nº publicación: US2016168627A1 16/06/2016

Solicitante:
NESTEC SA [CH]

Resumen de: WO2015007464A1

The present invention relates to predicting the risk of developing hypertriglyceridemia in a subject by quantitating the amount of enterobacteria, e.g., E. coli, in the subject's gastrointestinal system. The invention also relates to treating a subject with hypertriglyceridemia or at risk of having the condition.



traducir


 

METHODS FOR PRODUCING SALMONELLA O- ANTIGEN CAPSULES, COMPOSITIONS AND USES THEREOF

Nº publicación: US2016158333A1 09/06/2016

Solicitantes:
WHITE AARON P [CA]
PERERA SUMUNDU R [CA]
LAM SHIRLEY [CA]
GIBSON DEANNA L [CA]
UNIV SASKATCHEWAN [CA]
UNIVERSIYT OF BRITISH COLUMBIA [CA]

Resumen de: WO2015010185A1

Methods of purifying O-Ag capsules from an S. enterica NTS serovar, wherein the O- Ag capsule is substantially free of co-expressed cellulose and LPS, are described, as are immunogenic compositions comprising the O-Ag capsules and methods for treating, preventing and diagnosing Salmonella infections. Also described are constructs and methods for producing S. enterica NTS serovar mutants which over-express the O-Ag capsule.



traducir


 

METHODS FOR PRODUCING SALMONELLA O- ANTIGEN CAPSULES, COMPOSITIONS AND USES THEREOF

Nº publicación: US2016158333A1 09/06/2016

Solicitantes:
WHITE AARON P [CA]
PERERA SUMUNDU R [CA]
LAM SHIRLEY [CA]
GIBSON DEANNA L [CA]
UNIV SASKATCHEWAN [CA]
UNIVERSIYT OF BRITISH COLUMBIA [CA]

Resumen de: WO2015010185A1

Methods of purifying O-Ag capsules from an S. enterica NTS serovar, wherein the O- Ag capsule is substantially free of co-expressed cellulose and LPS, are described, as are immunogenic compositions comprising the O-Ag capsules and methods for treating, preventing and diagnosing Salmonella infections. Also described are constructs and methods for producing S. enterica NTS serovar mutants which over-express the O-Ag capsule.



traducir


 

NANOPORE BIOSENSORS FOR DETECTION OF PROTEINS AND NUCLEIC ACIDS

Nº publicación: JP2016516735A 09/06/2016

Resumen de: WO2014153625A1

Described herein are nanopore biosensors based on a modified cytolysin protein. The nanopore biosensors accommodate macromoiecules including proteins and nucleic acids, and may additionally comprise ligands with selective binding properties.



traducir


 

COMPOSITION FOR EVALUATING OR PREDICTING PATIENT'S THERAPEUTIC RESPONSE TO METFORMIN

Nº publicación: US2016160267A1 09/06/2016

Solicitante:
SNU R&DB FOUNDATION [KR]

Resumen de: WO2015008884A1

The present invention relates to a biomarker for evaluating or predicting patient's therapeutic response to metformin, and a use thereof. The present invention relates to a composition and kit for evaluating and predicting patient's therapeutic response to metformin, the composition and the kit each containing an agent capable of detecting at least one microorganism selected from the group consisting of Blautia, Shigella, and Clostridium. Further, the present invention relates to a method for detecting at least one microorganism selected from the group consisting of Blautia, Shigella, and Clostridium, from a sample of the patient, in order to provide information necessary for evaluating or predicting the response to metformin.



traducir


 

COMPOSITION FOR EVALUATING OR PREDICTING PATIENT'S THERAPEUTIC RESPONSE TO METFORMIN

Nº publicación: US2016160267A1 09/06/2016

Solicitante:
SNU R&DB FOUNDATION [KR]

Resumen de: WO2015008884A1

The present invention relates to a biomarker for evaluating or predicting patient's therapeutic response to metformin, and a use thereof. The present invention relates to a composition and kit for evaluating and predicting patient's therapeutic response to metformin, the composition and the kit each containing an agent capable of detecting at least one microorganism selected from the group consisting of Blautia, Shigella, and Clostridium. Further, the present invention relates to a method for detecting at least one microorganism selected from the group consisting of Blautia, Shigella, and Clostridium, from a sample of the patient, in order to provide information necessary for evaluating or predicting the response to metformin.



traducir


 

NANOPORE BIOSENSORS FOR DETECTION OF PROTEINS AND NUCLEIC ACIDS

Nº publicación: JP2016516735A 09/06/2016

Resumen de: WO2014153625A1

Described herein are nanopore biosensors based on a modified cytolysin protein. The nanopore biosensors accommodate macromoiecules including proteins and nucleic acids, and may additionally comprise ligands with selective binding properties.



traducir


 

MULTIFUNCTIONAL ORAL VACCINE BASED ON CHROMOSOME RECOMBINEERING

Nº publicación: HK1211980A1 03/06/2016

Solicitante:
US [US]

Resumen de: WO2014043637A1

A recombineered Salmonella typhi Ty21a, compositions and vaccines comprising such a Ty21a, and a method for recombineering comprising inserting a large antigenic region into a bacterial chromosome for the purpose of making multivalent vaccines to protect against one or more disease agents are described herein.



traducir


 

MULTIFUNCTIONAL ORAL VACCINE BASED ON CHROMOSOME RECOMBINEERING

Nº publicación: HK1211980A1 03/06/2016

Solicitante:
US [US]

Resumen de: WO2014043637A1

A recombineered Salmonella typhi Ty21a, compositions and vaccines comprising such a Ty21a, and a method for recombineering comprising inserting a large antigenic region into a bacterial chromosome for the purpose of making multivalent vaccines to protect against one or more disease agents are described herein.



traducir


 

Salmonella conjugate vaccines

Nº publicación: AU2014347722A1 02/06/2016

Solicitante:
GLAXOSMITHKLINE BIOLOG SA

Resumen de: EP2870974A1

The invention relates to a conjugate based on Vi polysaccharide which is fragmented and a carrier protein, to compositions comprising said conjugate and to methods for making said conjugates and compositions.



traducir


 

METHOD FOR PREPARING BACTERIAL POLYSACCHARIDE-MODIFIED RECOMBINANT FUSION PROTEIN AND USE THEREOF

Nº publicación: WO2016082597A1 02/06/2016

Solicitante:
INST OF BIOTECHNOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES CHINA [CN]

Resumen de: WO2016082597A1

Provided are a method for preparing a bacterial polysaccharide-modified recombinant fusion protein and a use thereof. The method comprises: the recombinant fusion protein and the neisseria meningitidis O-oligosaccharyltransferase PgIL are co-expressed in a bacteria defective in O-antigen ligase genes, and the polysaccharides which are endogenous or exogenous for the bacteria itself are connected to the recombinant fusion protein by the O-oligosaccharyltransferase PgIL, and the polysaccharide-modified recombinant fusion protein is thus obtained. The protein can be used for preparing antibodies and vaccines against bacterial polysaccharides.



traducir


 

Salmonella conjugate vaccines

Nº publicación: AU2014347722A1 02/06/2016

Solicitante:
GLAXOSMITHKLINE BIOLOG SA

Resumen de: EP2870974A1

The invention relates to a conjugate based on Vi polysaccharide which is fragmented and a carrier protein, to compositions comprising said conjugate and to methods for making said conjugates and compositions.



traducir


 

METHOD FOR PREPARING BACTERIAL POLYSACCHARIDE-MODIFIED RECOMBINANT FUSION PROTEIN AND USE THEREOF

Nº publicación: WO2016082597A1 02/06/2016

Solicitante:
INST OF BIOTECHNOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES CHINA [CN]

Resumen de: WO2016082597A1

Provided are a method for preparing a bacterial polysaccharide-modified recombinant fusion protein and a use thereof. The method comprises: the recombinant fusion protein and the neisseria meningitidis O-oligosaccharyltransferase PgIL are co-expressed in a bacteria defective in O-antigen ligase genes, and the polysaccharides which are endogenous or exogenous for the bacteria itself are connected to the recombinant fusion protein by the O-oligosaccharyltransferase PgIL, and the polysaccharide-modified recombinant fusion protein is thus obtained. The protein can be used for preparing antibodies and vaccines against bacterial polysaccharides.



traducir


 

CN105624079A

Nº publicación: CN105624079A 01/06/2016

 

CN105624078A

Nº publicación: CN105624078A 01/06/2016

 

CN105624079A

Nº publicación: CN105624079A 01/06/2016


 

Página 1 de 2 nextPage Mostrar por página

Volver